Open-Label Trial: A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity - Poulalhon, N; Begon, E; Lebbé, C (Br J Dermatol, 2007)
et al.